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Background—Depression, anxiety, and type D (“distressed”) personality (tendency to experience negative emotions paired
with social inhibition) have been associated with poor prognosis in coronary heart disease, but little is known about their
role in chronic heart failure. Therefore, we investigated whether these indicators of psychological distress are associated
with mortality in chronic heart failure.
Method and Results—Consecutive outpatients with chronic heart failure (n641; 74.3% men; mean age, 66.610.0 years)
filled out a 4-item questionnaire to assess mixed symptoms of anxiety and depression and the 14-item type D scale. End
points were defined as all-cause and cardiac mortality. After a mean follow-up of 37.615.6 months, 123 deaths (76
due to cardiac cause) were recorded. Cumulative hazard functions for elevated anxiety/depression symptoms differed
marginally for all-cause (P0.06), but not cardiac, mortality (P0.43); type D personality was associated with neither
all-cause mortality (P0.63) nor cardiac mortality (P0.87). In multivariable analyses, neither elevated anxiety/
depression symptoms nor type D personality was associated with all-cause mortality (hazard ratio [HR]1.18; 95% CI,
0.76 to 1.84; P0.45 and HR1.09; 95% CI, 0.67 to 1.77; P0.73, respectively) or cardiac mortality (HR1.13; 95%
CI, 0.63 to 2.04; P0.65 and HR1.16; 95% CI, 0.62 to 2.18; P0.67). In secondary analyses, a 1-point increase in
anxiety/depression (range, 0 to 16) was associated with an 8% increase in risk for all-cause mortality (HR1.08; 95%
CI, 1.01 to 1.15; P0.02).
Conclusions—Neither elevated anxiety/depression symptoms nor type D personality was associated with an increased risk
for all-cause or cardiac mortality. Future studies with adequate power and a longer follow-up duration are needed to
further elucidate the role of psychological distress in chronic heart failure. (Circ Heart Fail. 2010;3:261-267.)
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The incidence and prevalence of chronic heart failure(CHF) remain high despite improvements in treatment
strategies.1–3 Moreover, the burden of CHF is extensive
because it is associated with high mortality,3,4 frequent
hospital readmissions,5,6 and impaired health status.7,8 Vari-
ous clinical and demographic factors have been shown to
predict poor outcome, including reduced left ventricular
ejection fraction (LVEF), higher New York Heart Associa-
tion (NYHA) functional class, and older age.9–11
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Some studies suggest that symptoms of psychological
distress, such as anxiety and depression, have an adverse
effect on prognosis. However, findings on distress as an
associate of mortality in CHF remain inconclusive.12,13 In
addition, chronic psychological factors, such as type D
personality (the tendency to experience negative emotions
and inhibit self-expression), might be of interest in the
context of CHF.14,15 Previous research suggests that type D
personality may be associated with an increased risk for
anxiety/depression symptoms,16,17 impaired health status,18 and
cardiac mortality19 in patients with CHF and that this risk is
independent of traditional risk factors and markers of disease
severity.20–22
In this study, we examined whether symptoms of anxiety/
depression and type D personality were associated with
all-cause and cardiac mortality in outpatients with CHF,
independent of traditional risk factors and indicators of
disease severity.
Methods
Participants and Procedure
Between January 2003 and January 2008, 740 consecutive outpa-
tients with CHF were approached for participation in hospitals in the
southern regions of The Netherlands (ie, Tweesteden Hospital and St
Elisabeth Hospital, Tilburg; Amphia Hospital, Breda; and Zorgsaam
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Hospital, Zeeuws-Vlaanderen). Inclusion criteria were LVEF40%,
age 80 years, stable on medication for at least 1 month, and
absence of myocardial infarction (MI) and hospital admissions in the
month before inclusion. Patients were excluded in case of other
life-threatening comorbidities (eg, cancer), psychiatric comorbidity
(except for mood disorders), presence of evident cognitive impair-
ments, or insufficient understanding of the Dutch language to be able
to complete questionnaires. Of the 740 approached patients, 665
agreed to participate (87.0% response rate). Final analyses were
based on 641 patients. A flowchart of the patient selection is shown
in Figure 1. The mean age of the total sample was 66.610.0 years,
with 476 patients (74.3%) being men. All patients were treated
according to the most recent guidelines for CHF.23
Patients were approached for participation by their treating cardi-
ologist or heart failure nurse during their outpatient visit to the
cardiology department. They were contacted by telephone within 2
weeks after this visit with information about the study and were
asked to fill out a questionnaire to assess sociodemographic and
psychological variables. Questionnaires were returned in a stamped,
preaddressed envelope and checked for completeness. If patients did
not return the questionnaire within 2 weeks, they received a reminder
phone call or letter. The study was approved by the medical ethics
committees of the participating hospitals and was conducted
according to the Helsinki Declaration. All patients provided
written informed consent.
Sociodemographic and Clinical Variables
Purpose-designed questions in the questionnaire assessed sociode-
mographic characteristics, including sex, age, educational level,
current smoking, and marital status. Information on clinical variables
was obtained from the patients’ medical records and comprised
LVEF, NYHA functional class (I–II versus III–IV), cause (ischemic
versus nonischemic), time since diagnosis, cardiac history (ie,
previous MI, coronary artery bypass grafting, or percutaneous
coronary intervention), and comorbidities (ie, history of stroke or
transient ischemic attack, chronic obstructive pulmonary disease,
kidney disease, diabetes, hypercholesterolemia, hypertension, and
peripheral arterial disease). Information on prescribed medications
(ie, diuretics, spironolactone, angiotensin-converting enzyme inhib-
itors, -blockers, angiotensin II receptor blockers, calcium antago-
nists, statins, oral anticoagulants, digitalis, and aspirin) was collected
from the patients’ medical records at inclusion.
Psychological Distress
Symptoms of mixed anxiety/depression were assessed with the
Symptoms of Anxiety-Depression Index,24 because anxiety and
depression tend to co-occur in both healthy individuals and cardiac
patients.25,26 This 4-item scale, originally developed in post-MI
patients, consists of 2 items assessing anxious symptoms (tension
and restlessness) and 2 items assessing depressive symptoms (feeling
blue and hopelessness). Items are answered on a 5-point Likert scale,
ranging from 0 (not at all) to 4 (very much). Elevated anxiety/
depression symptoms were defined according to a previously defined
cutoff score of 3.24 The Symptoms of Anxiety-Depression Index is
internally consistent (Cronbach 0.86) and has been shown to
independently predict a diagnosis of clinical depression and a
composite of anxiety or depressive disorder.24
Type D personality was assessed with the 14-item type D scale.27
The 14-item type D scale consists of 2 subscales, negative affectivity
(eg, “I often feel unhappy”) and social inhibition (eg, “I find it hard
to start a conversation”), comprising 7 items each that are answered
on a 5-point Likert scale (range, 0 to 4). A standardized cutoff score
of 10 on both subscales is used to determine type D personality,27
because the interaction of negative affectivity and social inhibition,
rather than negative affectivity per se, has been shown to be
independently associated with poor clinical outcome.28 Both sub-
scales have good internal consistency (Cronbach 0.88 and 0.86,
respectively),27 are not confounded by mood status or disease
severity,29,30 and are stable during an 18-month period.30
End Points
All-cause mortality was the primary outcome of this study; cardiac
mortality (ie, death as a result of an exacerbation of CHF, sudden
cardiac death, ventricular fibrillation, or fatal MI) was the secondary
outcome. Information on the date and the cause of death was
retrieved from the patients’ medical records or by contacting the
general practitioner. Patients for whom the cause of death could not
be unambiguously determined were assigned to the all-cause mor-
tality group. Information on the end points was gathered in the first
week of February 2009. The mean follow-up period was 37.615.6
months (range, 12 to 73 months). Follow-up was complete (100%)
for all patients.
Statistical Analyses
Group differences were examined with 2 tests for dichotomous
variables and Student t tests for independent samples for continuous
variables. Cumulative survival curves for anxiety/depression symp-
toms (ie, high versus low) and type D personality (ie, present versus
absent) were constructed by using the Kaplan–Meier method. The
log-rank test was used to compare cumulative survival curves
between groups. By using an etiologic approach, multivariable Cox
regression models were used to examine the effect of psychological
distress on all-cause and cardiac mortality adjusting for all baseline
characteristics (ie, age, sex, having a partner, working status,
educational level, cause, time since diagnosis, LVEF, cardiac his-
tory, New York Heart Association class, diabetes, hypercholesterol-
emia, hypertension, kidney disease, stroke/transient ischemic attack,
chronic obstructive pulmonary disease, peripheral arterial disease,
smoking status, prescribed medications, and device therapy). In these
analyses, anxiety/depression symptoms and type D personality were
entered as dichotomous variables. In secondary analyses, continuous
variables were used for anxiety/depression symptoms, negative
affectivity, social inhibition, and the interaction between negative
affectivity and social inhibition. Hazard ratios (HRs) with their
corresponding 95% CIs for psychological distress are reported for
multivariable Cox regression analyses. Statistical analyses were
performed with SPSS for Windows (version 16.0; SPSS Inc, Chi-
cago, Ill). All tests were 2-tailed, and a P value of 0.05 was used
to indicate statistical significance.
Post hoc power calculations for Cox regression analysis were
performed with PASS 2008 (NCSS LLC, Kaysville, Utah). Power
was determined for the all-cause mortality models after assuming
population HRs of 1.3 and 1.5 for both anxiety/depression symptoms
and type D personality, respectively, because these estimates are
likely to be expected. R2 for both anxiety/depression symptoms and
type D personality with all other covariates was set at 0.20, which
was computed by regressing the independent variable on all covari-
Figure 1. Flowchart of patient selection.
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ates by logistic regression. The SDs of anxiety/depression symptoms
and type D personality were 0.44 and 0.40, respectively.
Results
Baseline Characteristics and Mortality
Participants and nonparticipants of the study differed on some
baseline characteristics, with nonparticipants having higher
rates of hypercholesterolemia, kidney disease, statin and
nitrate prescription, and a lower prescription rate for angio-
tensin-converting enzyme inhibitors (4.62224.30,
P0.001).
The prevalence of psychological distress was 26% for
elevated anxiety/depression symptoms and 20% for type D
personality in the total sample. The mean score for negative
affectivity was 7.136.38 (range, 0 to 28), 9.146.52 (range,
0 to 28) for social inhibition, and 2.473.21 (range, 0 to 16)
for anxiety/depression symptoms in the total sample. The
prevalence of elevated anxiety/depression symptoms in type
D patients was 63.3% (81 of 128).
Type D and non–type D patients differed on some baseline
characteristics, with type D patients more often having a
lower educational level and a lower prescription rate for oral
anticoagulants but a higher prescription rate for diuretics
(Table 1). In addition, some differences emerged when
stratifying by anxiety/depression symptoms: patients with
high levels of anxiety/depression symptoms were less likely
to have a partner and a lower educational level, but they were
more often classified as being in NYHA class III–IV, having
a lower prescription rates for -blockers but a higher pre-
scription rate for nitrates, and less likely being treated with
device therapy. At follow-up, 123 (19.2%) patients had died,
for whom 76 (12.4%) deaths were attributable to a cardiac
cause.
Psychological Distress and All-Cause Mortality
Cumulative hazard functions marginally differed for elevated
versus nonelevated anxiety/depression symptoms (log-rank
23.67, P0.06) (Figure 2a) but not for type D versus
non–type D personality (log-rank 20.24, P0.64; Figure 2b).
Neither elevated anxiety/depression symptoms nor type D
personality was significantly associated with all-cause mor-
tality in multivariable Cox regression analysis, after adjusting
for all possible confounders (Table 2). Significant covariables
in the model were older age, male sex, having no partner,
current smoking, lower LVEF, and comorbid kidney disease
(all P0.05).
In secondary multivariable analyses, by using continuous
scores, a 1-point increase in anxiety/depression score (range, 0 to
16) was associated with an 8% increase in risk for all-cause
mortality (HR1.08; 95% CI, 1.01 to 1.15; P0.02). Negative
affectivity, social inhibition, and the interaction of negative
affectivity and social inhibition were not independently associ-
ated with all-cause mortality (all P0.05).
Psychological Distress and Cardiac Mortality
Cumulative hazard functions differed neither for elevated
versus nonelevated anxiety/depression symptoms (log-rank
20.62; P0.43) nor for type D versus non–type D person-
ality (log-rank 20.03; P0.87).
Neither elevated anxiety/depression symptoms nor type D
personality was independently associated with cardiac mor-
tality in multivariable Cox regression analyses (Table 2).
Male sex, lower LVEF, and comorbid kidney disease were
significant covariables in the model for cardiac mortality (all
P0.05).
In secondary multivariable analyses with continuous
scores, neither anxiety/depression symptoms nor negative
affectivity or the interaction of negative affectivity and social
inhibition (all P.05) was independently associated with
cardiac mortality.
Post hoc power calculations for the population HRs of 1.3
and 1.5 for anxiety/depression symptoms demonstrated that
the power was 0.21 and 0.42, respectively. Post hoc power
calculations for these HRs for type D personality demon-
strated a power of 0.18 and 0.36. Power calculations derived
from bootstrapping methods31 yielded similar results (results
not shown).
Discussion
In this study, we examined the associations between psycho-
logical distress (ie, anxious/depression symptoms and type D
personality) and mortality in outpatients with CHF. Neither
elevated anxiety/depression symptoms nor type D personality
was associated with all-cause or cardiac mortality at a mean
follow-up of 38 months. Secondary analyses, with continuous
scores, showed that higher levels of anxious/depression
symptoms were independently associated with all-cause but
not with cardiac mortality.
The current finding that elevated anxiety/depression scores
are not associated with all-cause mortality is in line with a
previous study that failed to demonstrate an association
between minor depression and all-cause mortality in a mixed
sample of hospitalized patients with CHF and outpatients.32
Our findings are in contrast with those of a recent study,
showing that elevated depression symptoms were indepen-
dently associated with all-cause mortality in outpatients with
CHF with comorbid atrial fibrillation.33 However, both stud-
ies used different samples and other instruments to assess
psychological distress, which hampers comparability with
this study.
The finding that, in secondary analyses, higher levels of
anxiety/depression (continuous scores) were associated with
all-cause mortality, corroborates previous studies, showing
that higher levels of depressive symptoms incur an increased
and independent risk for all-cause mortality in outpatients
with CHF33–36 but are in contrast with a study finding no such
evident association.37 Although 2 studies in outpatients have
shown that higher levels of depressive symptoms were
independently associated with cardiac mortality at 2- and
6-year follow-up,38,39 we were not able to confirm these
findings.
Studies on the role of anxious symptoms in the context of
mortality in outpatients with CHF have shown mixed re-
sults.34,35 Furthermore, 1 study in hospitalized patients
showed that anxious symptoms were not associated with
mortality at 1-year follow-up, whereas depressive symptoms
were.40 In this study, we focused on the co-occurrence of
anxiety and depression, rather than anxiety and depressive
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symptoms separately.24 Because depression and anxiety are
known to frequently co-occur,26,41 this approach may serve as
a more realistic representation of patient symptomatology.
The findings of this study are in line with previous studies
that have demonstrated that type D personality is associated
with anxiety42 and depression.16,17 In the current sample, the
prevalence of elevated anxiety/depression symptoms was
63% in type D patients. However, the findings related to
mortality contradict the results of previous studies, demon-
strating that type D personality was independently associated
with mortality in outpatients with CHF,19 post-MI patients
with a decreased LVEF,20 and heart transplant recipients.43
One explanation for this discrepancy might be that most of
the previous studies have focused on long-term effects, with
follow-ups generally ranging from 5 to 10 years, whereas in
the this study, the mean follow-up period was only 3 years.
Previously, it has been argued that personality might exert its
adverse effects on prognosis, especially in the long term.19,44
The relatively low prevalence of type D personality, ie, 20%
in the current sample compared with 25% to 30% in patients
Table 1. Significant Baseline Characteristics Stratified by Type D Personality and Anxiety/Depression Symptoms
Total Sample
(N641)
Type D
(n128)
Non–Type D
(n513) P
Elevated
Anxiety/Depression
Symptoms
(n169)
No Elevated
Anxiety/Depression
Symptoms
(n472) P
Sociodemographics
Male sex 476 (74.3) 93 (72.7) 383 (74.7) 0.64 123 (72.8) 353 (74.8) 0.61
Age, mean (SD), y 66.6 (10.0) 66.3 (10.1) 67.8 (9.8) 0.14 66.9 (10.0) 66.5 (10.0) 0.63
Having a partner 465 (72.5) 85 (66.4) 380 (74.1) 0.08 105 (62.1) 360 (76.3) 0.001
Currently working 86 (13.4) 12 (9.4) 74 (14.4) 0.13 19 (11.2) 67 (14.2) 0.33
Lower educational level* 223 (34.8) 55 (43.0) 168 (32.7) 0.03 73 (43.2) 150 (31.8) 0.008
Clinical variables
Ischemic etiology 369 (57.6) 74 (57.8) 295 (57.5) 0.95 104 (61.5) 265 (56.1) 0.22
Time since diagnosis,
mean (SD), mo
46.1 (48.4) 50.2 (61.1) 45.1 (44.3) 0.29 47.6 (55.7) 45.6 (45.7) 0.64
LVEF, mean (SD) 31.4 (7.2) 31.6 (7.3) 31.4 (7.1) 0.83 31.5 (7.6) 31.4 (7.0) 0.86
Cardiac history† 392 (61.2) 82 (64.1) 310 (60.4) 0.45 111 (65.7) 281 (59.5) 0.16
NYHA class III–IV 226 (30.7) 51 (39.8) 175 (34.1) 0.23 75 (44.4) 151 (32.0) 0.004
Diabetes mellitus 164 (25.6) 32 (25.0) 132 (25.7) 0.87 45 (26.6) 119 (25.2) 0.72
Hypercholesterolemia 331 (51.6) 68 (53.1) 263 (51.3) 0.71 88 (52.1) 243 (51.5) 0.90
Hypertension 254 (39.6) 51 (39.8) 203 (39.6) 0.96 75 (44.4) 179 (37.9) 0.14
Kidney disease 70 (10.9) 17 (13.3) 53 (10.3) 0.34 21 (12.4) 49 (10.4) 0.47
Stroke/TIA 92 (14.4) 12 (9.4) 80 (15.6) 0.07 24 (14.2) 68 (14.4) 0.95
COPD 102 (15.9) 22 (17.2) 80 (15.6) 0.66 32 (18.9) 70 (14.8) 0.21
PAD 79 (12.3) 21 (16.4) 58 (11.3) 0.12 23 (13.6) 56 (11.9) 0.55
Currently smoking 154 (24.0) 26 (20.3) 128 (25.0) 0.27 37 (21.9) 117 (24.8) 0.45
Medication
ACE inhibitors 439 (68.5) 85 (66.4) 354 (69.0) 0.57 107 (63.3) 332 (70.3) 0.09
-blockers 432 (67.4) 85 (66.4) 347 (67.6) 0.79 102 (60.4) 330 (69.9) 0.02
ARBs 141 (22.0) 32 (25.0) 109 (21.2) 0.36 41 (24.3) 100 (21.2) 0.41
Calcium antagonists 80 (12.5) 22 (17.2) 58 (11.3) 0.07 24 (14.2) 56 (11.9) 0.43
Nitrates 163 (25.4) 40 (31.3) 123 (24.0) 0.09 53 (31.4) 110 (23.3) 0.04
Digoxin 143 (22.3) 30 (23.4) 113 (22.0) 0.73 36 (21.3) 107 (22.7) 0.71
Spironolactone 130 (20.3) 24 (18.8) 106 (20.7) 0.63 34 (20.1) 96 (20.3) 0.95
Oral anticoagulants 309 (48.2) 51 (39.8) 258 (50.3) 0.03 77 (45.6) 232 (49.2) 0.42
Statins 355 (55.4) 71 (55.5) 284 (55.4) 0.98 93 (55.0) 262 (55.5) 0.91
Aspirin 257 (40.1) 54 (42.2) 203 (39.6) 0.59 64 (37.9) 193 (40.9) 0.49
Diuretics 469 (73.2) 104 (81.3) 365 (71.2) 0.02 132 (78.1) 337 (71.4) 0.09
Device therapy‡ 96 (15.0) 21 (16.4) 75 (14.6) 0.61 17 (10.1) 79 (16.7) 0.04
Data are presented as n (%) unless otherwise stated. ARBs indicates angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease;
NYHA, New York Heart Association functional class; PAD, peripheral arterial disease; TIA, transient ischemic attack.
*Defined as primary school or lower.
†Coronary artery bypass grafting, MI, or percutaneous coronary intervention.
‡Either single, biventricular pacemaker or implantable cardioverter defibrillator.
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with coronary artery disease,22 may provide another explana-
tion. A lower prevalence of type D personality in CHF might
be a consequence of type D patients being more likely to die
in earlier stages of cardiac disease before developing CHF.
The current findings are generally contradictory to those of
previous studies suggesting that psychological distress might
predict mortality in CHF.19,33,38,39 However, both anxiety and
depressive symptoms and type D personality have been
consistently linked to poor patient-centered outcomes such as
impaired health status,16,18,45–47 and type D personality has
been shown to predict increased levels of depression16,21 and
anxiety42,48 across different types and stages of cardiac
disease. These patient-centered outcomes are important in
their own right because they may serve as performance
measures in clinical practice to optimize clinical care.49,50
Nevertheless, this study provides a new, critical perspective
on the role of psychological distress in the context of cardiac
disease, and CHF in particular, that warrants further
exploration.
The results of this study should be interpreted with some
caution. First, the observed power of this study was modest.
Second, the follow-up period was relatively short, with a
mean follow-up of 3 years, whereas other studies on person-
ality have primarily focused on the long-term effects. Third,
anxious and depressive symptoms were assessed by means of
self-report, and no information on a clinical diagnosis of
anxiety of depression was obtained. Furthermore, the gener-
alizability of the findings to the North American setting is
somewhat hampered because of the lack of minorities in this
study. Finally, no systematic approach to adjudication of
cardiac mortality was implemented in this study. Strengths of
this study include the multicenter design, with the assessment
of both chronic and episodic measures of psychological
distress and the co-occurrence of anxiety/depression symp-
toms adding to the existing literature.
To conclude, the findings of this study indicate that neither
elevated anxiety/depression symptoms nor type D personality
was associated with all-cause and cardiac mortality. In
secondary analyses, continuous scores of anxious/depressive
symptoms were independently associated with all-cause but
not with cardiac mortality. Future studies with longer
follow-up and adequate power are needed to further explore
the complex nature of psychological distress as a predictor of
the clinical course of CHF.
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Figure 2. Cumulative survival curves for all-cause
mortality.
Table 2. Multivariable Model of Psychological Distress
and Mortality*
All-Cause Mortality
(n123)
Cardiac Mortality
(n76)
HR 95% CI P HR 95% CI P
Anxiety/depression
symptoms†
1.18 0.76 to 1.84 0.45 1.13 0.63 to 2.04 0.65
Type D
personality†
1.09 0.67 to 1.77 0.73 1.16 0.62 to 2.18 0.67
*Model adjusted for age, sex, having a partner, working status, educational
level, etiology, time since diagnosis, LVEF, cardiac history, NYHA class,
diabetes, hypercholesterolemia, hypertension, kidney disease, stroke/transient
ischemic attack, chronic obstructive pulmonary disease, peripheral arterial
disease, smoking status, prescribed medications, and device therapy.
†Hazard ratios (HRs) for dichotomous scores.
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CLINICAL PERSPECTIVE
Chronic heart failure is a serious condition and a main reason for mortality and morbidity worldwide. Previous studies have
suggested that psychological distress may be associated with mortality in chronic heart failure. This study examined the
influence of both episodic (anxiety/depression symptoms) and chronic (type D personality—tendency to experience
negative emotions and inhibit self-expression) psychological distress on all-cause and cardiac mortality during a mean
follow-up period of 38 months in 641 patients enrolled in a multicenter, prospective, observational cohort study. Neither
elevated anxiety/depression symptoms nor type D personality was associated with all-cause and cardiac mortality after
controlling for baseline characteristics (ie, sociodemographics, clinical characteristics, disease severity, comorbidities, and
prescribed medications). In contrast, higher levels of anxiety/depression symptoms were associated with a 1.08 hazard ratio
(95% confidence interval, 1.01 to 1.15; P0.02) for all-cause mortality, with a 1-point increase in anxious/depressive
symptoms being independently associated with an 8% increased risk. The current findings are inconsistent with previous
studies on the role of anxiety and depression and type D personality as predictors of mortality in different stages of cardiac
disease. Because chronic heart failure represents the end stage of heart disease, psychological factors may play less of a
role in survival than in patients at earlier stages of disease. Given the modest power of the study, findings should be
interpreted with some caution. To conclude, although this study did not unambiguously demonstrate an effect of
psychological factors on survival, they are important in their own right because they influence quality of life.
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